Abstract: These mutations included: L109R, Q129R, M133L, S143L and D144E with overall prevalence of 18.9% (95% CI [9.5-34.2]).
Result: The M133L and D144E mutations that are vaccine-escape mutants, affecting HBV detection and immunoglobulin therapy were found each in a single patient.
Table: M133L
Molecular characterization of hepatitis B virus in blood donors in Botswana.
Result: Another significant VEM, sG145K/R, was identified in six studies and sM133L/T, associated with VEM, immunoglobulin and diagnostic escape mutation, was identified in seven studies (Fig 2).
Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe.
Method: Among them, sP120S/T/A, sT126N/S, sQ129R/N, sT131I/N, sM133I/L, sP142S, sD144A/E, sG145A/R were known to act as vaccine-escape mutations.
Method: We determined the prevalence of 29 immune-associated escape mutations (sQ101K, sT114R, PMID: 29663445
2018
Journal of medical virology
Abstract: In addition, sQ101 K, sT131N, and sM133L were more frequently discovered in group I with significant difference (P < 0.05).
Substantial variation in the hepatitis B surface antigen (HBsAg) in hepatitis B virus (HBV)-positive patients from South Africa: Reliable detection of HBV by the Elecsys HBsAg II assay.
Abstract: All occult HBV infection-associated Y100C and common diagnostic and vaccine-escape-associated P120T, G145R, K122R, M133L, M133T, Q129H, G130N, and T126S mutations were reliably detected by the assay, which consistently detected the presence of HBsAg in all 179 samples including samples with 11 novel mutations.
Hepatitis B infection among HIV infected individuals in Gabon: Occult hepatitis B enhances HBV DNA prevalence.
Method: In addition, we looked for Vaccine Escape Mutants (VEMs) and polymorphic mutations outside (Y100C, Q101H, S117N, T118R and P120S) and within the HBsAg immuno-dominant 'a' determinant (I/T126A/N, A128V, Q129H/R, G130N, M133L/T, K141E, S143L, D144A/H/E and G145R).
HBV genotypes and drug resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected patients.
Method: The sequences were examined for known vaccine escape mutations (sG145R/A, sP142S, sI/T126A/N/I/S, sQ129H/R, sM133L, sD144A/E, sP120S/E, sK141E, sP134I, and sT116N), immunoprophylaxis escape mutations (
Molecular characterization of hepatitis B virus in Vietnam.
4Method: The S gene sequence was analyzed for mutations in the ""a"" determinant region (T116 N, P120S/T, I/T126S/A, Q129H/R, M133 L/T, K141E, P142S, D144E, and G145R), and other virulence associated mutations (N3S,
5Result: Among the isolates, 8.1% (11/135) had a mutation in the ""a"" determinant region including 2.2% (3/135) P120S/T, 2.2% (3/135) I/T126S/A, 3% (4/135) M133 L/T and 0.7% (1/135) G145R."
Prevalence of S gene mutations within the major hydrophilic region of hepatitis B virus in patients in Dongguan, southern China.
Abstract: Furthermore, the mutations sY100C, sQ101R/K, sS114A, sP120T, sT/I126A/N/S, sQ129R, sM133L/T/S and sG145R/A were prevalent in at least one genotype, with a frequency higher than 1%, which indicated that these mutations were relatively common.
HBV mutation literature information.
PMID: 
2019
PeerJ
Browser Board
Co-occurred Entities
Filtrator
ViMRT